Overview

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Status:
Not yet recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Collaborator:
Sunshine Lake Pharma Co., Ltd.